Ribbon-1: Randomized, Double-blind, Placebo, Phase III Trial of First Line Chemo With or Without Bevacizumab for MBC
Efficacy of BSI-201, a PARP-Inhibitor in combination with Gemcitabine/Carboplatin in Triple Negative Breast Cancer: Randomized Phase II trial